There are currently no generic Onglyza products available on the market. The medication is currently under the protection of a patent that prevents other companies from manufacturing a generic version. As soon as this patent expires, other drug companies are expected to begin producing generic versions.
Is a Generic Version of Onglyza Available?
Onglyza™ (saxagliptin) is a prescription medication approved for treating type 2 diabetes. It belongs to a relatively new class of diabetes medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors.
Onglyza is manufactured by Bristol-Myers Squibb (BMS) and is marketed by BMS and AstraZeneca Pharmaceuticals LP. At this time, generic Onglyza is not available.
When Will Generic Onglyza Be Available?
The first patent for Onglyza currently expires in February 2021. This is the earliest predictable date that a generic version of Onglyza could become available. However, there are other circumstances that could come up to extend or shorten the exclusivity period of Onglyza. This could include such things as lawsuits or other patents for specific Onglyza uses.
Once the medicine goes off patent, there may be several companies that will begin manufacturing a generic Onglyza drug.
Is Saxagliptin a Generic Form of Onglyza?
The answer is no. Saxagliptin is the active ingredient in Onglyza but is not a generic version of the medication. This is confusing because the active ingredient of any drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine.
In order for there to be a generic version of a medicine, the original medicine must have gone off patent, and another company besides the original manufacturer must make the product.